Abbott and mAbxience partnership for biosimilars in emerging markets

Home/Pharma News | Posted 14/11/2023 post-comment0 Post your comment

Abbott and mAbxience announced on 20 September 2023 that they had entered into a strategic partnership to commercialize several biosimilars in Latin America and other emerging markets.

Shaking hands V13D29

Under the terms of the agreement, mAbxience, a Fresenius Kabi majority-owned group [1], will manufacture the biosimilars in their state-of-the art and good manufacturing practices (GMP)-approved facilities in Spain and Argentina. mAbxience will also be responsible for driving the clinical milestones for some of the molecules still undergoing development. The biosimilars, focusing on oncology, women’s health and respiratory disease, will be commercialized by Abbott. This will occur in the emerging markets of Latin America, Southeast Asia, the Middle East, and Africa.

This new agreement expands on that initiated in 2018, whereby the two companies were able to provide various treatment options for two oncology biosimilars in countries across Latin America including Columbia, Chile, Peru and various countries in Central America. First molecules expected to launch as early as 2025, offering new treatment options that leverage the latest in scientific breakthroughs for people in emerging markets.

mAbxience has entered other such partnerships to broaden its reach globally. For example, they have entered a partnership with HK inno.N in South Korea, to commercialise a denosumab biosimilar [2].

Related article
Fresenius Kabi signs marketing agreement for adalimumab biosimilar

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Alianza entre Abbott y mAbxience para los biosimilares en los mercados emergentes

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Alianza entre Abbott y mAbxience para los biosimilares en los mercados emergentes

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Fresenius Kabi acquire mAbxience and Ivenix []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 14]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. HK inno.N–mAbxience partnership in Korea and Coherus advances in the US[]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 14]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010